Coya Therapeutics competes with various biotechnology and pharmaceutical enterprises developing advanced cell therapies and immunotherapies for neurodegenerative and autoimmune conditions. Competitors include clinical-stage firms focusing on regulatory T cell (Treg) modulation, neuroinflammation pathways, and targeted biologic treatments for diseases like amyotrophic lateral sclerosis (ALS) and Alzheimer's.